Bandoh Nobuyuki, Akahane Toshiaki, Goto Takashi, Kono Michihisa, Ichikawa Haruyuki, Sawada Takahiro, Yamaguchi Tomomi, Nakano Hiroshi, Kawase Yumiko, Kato Yasutaka, Kamada Hajime, Harabuchi Yasuaki, Shimizu Kazuo, Nishihara Hiroshi
Department of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Department of Biology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Oncol Lett. 2018 Dec;16(6):7278-7286. doi: 10.3892/ol.2018.9538. Epub 2018 Oct 2.
Thyroid carcinoma (TC) has characteristic genetic alterations, including point mutations in proto-oncogenes and chromosomal rearrangements that vary by histologic subtype. Recent developments in next-generation sequencing (NGS) technology enable simultaneous analysis of cancer-associated genes of interest, thus improving diagnostic accuracy and allowing precise personalized treatment for human cancer. A total of 50 patients who underwent thyroidectomy between 2014 and 2016 at Hokuto Hospital were enrolled. Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections and quantified. Targeted regions of 24 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina MiSeq platform. Subjects included 30 patients with papillary carcinoma (PC), two with PC tall cell variant (TVPC), two with PC follicular variant (FVPC), eight with follicular carcinoma, seven with poorly differentiated carcinoma (PDC), and one with anaplastic carcinoma (AC). The V600E mutation was present in 25 of 30 (83%) patients with PC, 2 of 2 (100%) patients with TVPC, 6 of 7 (86%) patients of PDC, and one patient with AC. mutations were present in 3 of 30 (delPV104P, A1046T and C420R; 10%) patients with PC and 1 of 7 (H1047R; 14%) patients with PDC. The mutation was present in 1 of 30 (R306*; 3.3%) patients with PC and 1 of 7 (Q152*; 14%) patients with PDC. The mutation was present in 1 of 2 (Q61K, 50%) patients with FVPC. Statistical analysis showed that patients without the V600E mutation had advanced pathologic T and N stages compared with those with the mutation (P=0.047 and P=0.019, respectively). The V600E mutation was not correlated with overall and disease-free survival in patients with PC. A patient with PC with a mutation in (K852Q) and the mutation had an aggressive course with multiple bone and lung metastases. Detection of mutations in cancer-associated genes using NGS could enhance the understanding of the clinical behavior of TC.
甲状腺癌(TC)具有特征性的基因改变,包括原癌基因中的点突变和染色体重排,这些改变因组织学亚型而异。下一代测序(NGS)技术的最新进展能够同时分析感兴趣的癌症相关基因,从而提高诊断准确性并实现对人类癌症的精确个性化治疗。纳入了2014年至2016年期间在北斗医院接受甲状腺切除术的50例患者。从福尔马林固定、石蜡包埋的组织切片中提取总DNA并进行定量。通过PCR扩增24个癌症相关基因的靶向区域,使用Illumina MiSeq平台进行条形码标记和测序。受试者包括30例乳头状癌(PC)患者、2例PC高细胞变体(TVPC)患者、2例PC滤泡变体(FVPC)患者、8例滤泡癌患者、7例低分化癌(PDC)患者和1例未分化癌(AC)患者。V600E突变存在于30例PC患者中的25例(83%)、2例TVPC患者中的2例(100%)、7例PDC患者中的6例(86%)以及1例AC患者中。BRAF突变存在于30例PC患者中的3例(delPV104P、A1046T和C420R;10%)以及7例PDC患者中的1例(H1047R;14%)。NRAS突变存在于30例PC患者中的1例(R306*;3.3%)以及7例PDC患者中的1例(Q152*;14%)。HRAS突变存在于2例FVPC患者中的1例(Q61K,50%)。统计分析表明,与携带V600E突变的患者相比,未携带该突变的患者病理T和N分期更高(分别为P=0.047和P=0.019)。V600E突变与PC患者的总生存期和无病生存期无关。1例携带BRAF突变(K852Q)和NRAS突变的PC患者病程侵袭,伴有多处骨和肺转移。使用NGS检测癌症相关基因中的突变可增强对TC临床行为的理解。